Rituxan/mabthera To Maintain The Top Position In Cancer Mabs
As per RNCOSs new research report entitled Cancer Monoclonal Antibodies Market to 2015
, cancer represents the fastest growing and one of the most attractive therapeutic segments in the global pharmaceutical market. Among the several drug classes for cancer treatment, antineoplastics mAbs are the leading ones. Key factors, such as fast increase in the number of new cancer cases and the emergence of innovative technologies led to create a US$ 21 Billion worldwide market for antineoplastic mAbs in 2011. Fuelled by ever-increasing cancer cases globally, the market for the same is portraying an optimistic future outlook, worth17 Million by the end of 2020.
Our research report has found that four drugs currently dominate the global antineoplastics mAbs market, including Roches Avastin (bevacizumab), MabThera (rituximab), and Herceptin (trastuzumab); and BMS/Mercks Erbitux. Rituximab is known as Rituxan in the US, Japan, and Canada, and MabThera in Europe. Drugs sales are likely to have increased by around 7% and reached a market worth US$ 6.8 Billion by the end of 2011. Though in the coming future, Rituxan will face a threat from the entry of bio-similar versions, it is likely to maintain its dominance as the market-leading agent and is anticipated to advance at a CAGR of 5.4% during 2012-2015.
The report investigates and analyzes all the key developments of cancer mAbs market throughout the world. It also identifies the possible growth areas in terms of pipeline products and provides an in-depth analysis on the leading drugs under development with reference to their manufacturers and other key details. It also covers an exhaustive research on the country-level cancer mAbs market and offers a broad overview of the current developments.
The report, which is an outcome of prudent analysis and extensive research on the antineoplastic mAbs market, is spread in over 100 pages. It also provides future forecasts for the overall industry and key sections/areas on the basis of past trends, challenges, opportunities for expansion and economic and judgmental analysis. Further, the report illustrates about the approved mAbs, along with their recent industry developments to provide a balanced outlook on the potentials of the growing market.
For FREE SAMPLE of this report visit: http://www.rncos.com/Report/IM375.htm
Some of our Related Reports are:
-Indian Healthcare - New Avenues for Growth
(http://www.rncos.com/Report/IM151.htm)
-Insulin Delivery Systems Market Forecast to 2014
(http://www.rncos.com/Report/IM369.htm)
-Global Genetic Testing Market Analysis (http://www.rncos.com/Report/IM352.htm)
-US Diagnostic Market Outlook 2014 (http://www.rncos.com/Report/IM298.htm)
-Global In Vitro Diagnostic Market Analysis (http://www.rncos.com/Report/IM103.htm)
Check Related REPORTS on: http://www.rncos.com/Healthcare_Industry.htm
by: Shushmul Maheshwari
Suffering From Acute Liver Damage? Take The Help Of A Tylenol Attorney Breast Cancer Treatment In India Under Renowned Cancer Surgeons Liver Disease Cleanse Your Arteries With Natural Blood Pressure Herbal Treatments Proper Physical Therapy Treatments Give Enormous Relief From Pain When Conventional Treatments Are Not Enough To Look Good Big Laptop Shop Delivers Perfect Student Laptop Brands Blogs For Cancer Patients Turmeric Tea Shows Promise In Anti-cancer Fight Cancers Will Catch A Tartar Techniques Concerning How To Manage Many Forms Of Cancer Generating That Nasty Outdated Many Forms Of Cancer Flex In Your Will Using 3 Eczema Natural Treatments